minocycline and Demyelinating-Diseases

minocycline has been researched along with Demyelinating-Diseases* in 16 studies

Trials

2 trial(s) available for minocycline and Demyelinating-Diseases

ArticleYear
Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.
    The New England journal of medicine, 2017, 06-01, Volume: 376, Issue:22

    On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis.. During the period from January 2009 through July 2013, we randomly assigned participants who had had their first demyelinating symptoms within the previous 180 days to receive either 100 mg of minocycline, administered orally twice daily, or placebo. Administration of minocycline or placebo was continued until a diagnosis of multiple sclerosis was established or until 24 months after randomization, whichever came first. The primary outcome was conversion to multiple sclerosis (diagnosed on the basis of the 2005 McDonald criteria) within 6 months after randomization. Secondary outcomes included conversion to multiple sclerosis within 24 months after randomization and changes on magnetic resonance imaging (MRI) at 6 months and 24 months (change in lesion volume on T. A total of 142 eligible participants underwent randomization at 12 Canadian multiple sclerosis clinics; 72 participants were assigned to the minocycline group and 70 to the placebo group. The mean age of the participants was 35.8 years, and 68.3% were women. The unadjusted risk of conversion to multiple sclerosis within 6 months after randomization was 61.0% in the placebo group and 33.4% in the minocycline group, a difference of 27.6 percentage points (95% confidence interval [CI], 11.4 to 43.9; P=0.001). After adjustment for the number of enhancing lesions at baseline, the difference in the risk of conversion to multiple sclerosis within 6 months after randomization was 18.5 percentage points (95% CI, 3.7 to 33.3; P=0.01); the unadjusted risk difference was not significant at the 24-month secondary outcome time point (P=0.06). All secondary MRI outcomes favored minocycline over placebo at 6 months but not at 24 months. Trial withdrawals and adverse events of rash, dizziness, and dental discoloration were more frequent among participants who received minocycline than among those who received placebo.. The risk of conversion from a clinically isolated syndrome to multiple sclerosis was significantly lower with minocycline than with placebo over 6 months but not over 24 months. (Funded by the Multiple Sclerosis Society of Canada; ClinicalTrials.gov number, NCT00666887 .).

    Topics: Actuarial Analysis; Administration, Oral; Adult; Anti-Bacterial Agents; Demyelinating Diseases; Disease Progression; Dizziness; Double-Blind Method; Exanthema; Female; Humans; Intention to Treat Analysis; Life Tables; Magnetic Resonance Imaging; Male; Middle Aged; Minocycline; Multiple Sclerosis; Risk; Tooth Discoloration

2017
Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2014, Volume: 20, Issue:4

    The 2005 and 2010 McDonald criteria utilize magnetic resonance imaging (MRI) to provide evidence of disease dissemination in space (DIS) and time (DIT) for the diagnosis of multiple sclerosis (MS) in patients who have clinically isolated syndromes (CIS).. Data from 109 CIS patients not satisfying the 2005 criteria at entry into a randomized controlled minocycline trial were analyzed to determine the proportion who would have been diagnosed with MS at screening based on 2010 criteria. The impact of including symptomatic, as well as asymptomatic, MRI lesions to confirm DIT was also explored.. Thirty percent (33/109) of patients, retrospectively, met the 2010 criteria for a diagnosis of MS at baseline. When both symptomatic and asymptomatic lesions were used to confirm DIT, three additional patients met the 2010 criteria. There was a significant 10.1% increase in the proportion of patients who met the 2010 DIS criteria, compared with the 2005 DIS criteria; however, two patients satisfied the 2005 DIS but not 2010 DIS criteria.. Using 2010 McDonald criteria, 30% of the CIS patients could be diagnosed with MS using a single MRI scan. Inclusion of symptomatic lesions in the DIT criteria further increases this proportion to 33%.

    Topics: Adolescent; Adult; Canada; Demyelinating Diseases; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Minocycline; Multiple Sclerosis; Neuroprotective Agents; Practice Guidelines as Topic; Young Adult

2014

Other Studies

14 other study(ies) available for minocycline and Demyelinating-Diseases

ArticleYear
Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:13

    In the trial of Minocycline in Clinically Isolated Syndrome (MinoCIS), minocycline significantly reduced the risk of conversion to clinically definite multiple sclerosis (CDMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in MS, and minocycline modulates matrix metalloproteinases (MMPs).. To assess the value of blood NfL and GFAP as a biomarker of baseline and future disease activity and its utility to monitor treatment response in minocycline-treated patients with clinically isolated syndrome (CIS).. We measured NfL, GFAP, and MMPs in blood samples from 96 patients with CIS from the MinoCIS study and compared biomarkers with clinical and radiologic characteristics and outcome.. At baseline, NfL levels correlated with T. Blood NfL levels are associated with measures of disease activity in CIS and have prognostic value. Minocycline increased NfL levels at month 3, but reduced GFAP and MMP-7 levels.

    Topics: Biomarkers; Demyelinating Diseases; Gadolinium; Glial Fibrillary Acidic Protein; Humans; Intermediate Filaments; Matrix Metalloproteinase 7; Minocycline; Multiple Sclerosis; Neurofilament Proteins

2022
Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis.
    The New England journal of medicine, 2017, 08-24, Volume: 377, Issue:8

    Topics: Demyelinating Diseases; Humans; Magnetic Resonance Imaging; Minocycline; Multiple Sclerosis

2017
Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis.
    The New England journal of medicine, 2017, 08-24, Volume: 377, Issue:8

    Topics: Demyelinating Diseases; Humans; Magnetic Resonance Imaging; Minocycline; Multiple Sclerosis

2017
Minocycline prevents osmotic demyelination associated with aquaresis.
    Kidney international, 2014, Volume: 86, Issue:5

    Overly rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome (ODS). Minocycline protects ODS associated with overly rapid correction of chronic hyponatremia with hypertonic saline infusion in rats. In clinical practice, inadvertent rapid correction frequently occurs due to water diuresis, when vasopressin action suddenly ceases. In addition, vasopressin receptor antagonists have been applied to treat hyponatremia. Here the susceptibility to and pathology of ODS were evaluated using rat models developed to represent rapid correction of chronic hyponatremia in the clinical setting. The protective effect of minocycline against ODS was assessed. Chronic hyponatremia was rapidly corrected by 1 (T1) or 10 mg/kg (T10) of tolvaptan, removal of desmopressin infusion pumps (RP), or administration of hypertonic saline. The severity of neurological impairment in the T1 group was significantly milder than in other groups and brain hemorrhage was found only in the T10 and desmopressin infusion removal groups. Minocycline inhibited demyelination in the T1 group. Further, immunohistochemistry showed loss of aquaporin-4 (AQP4) in astrocytes before demyelination developed. Interestingly, serum AQP4 levels were associated with neurological impairments. Thus, minocycline can prevent ODS caused by overly rapid correction of hyponatremia due to water diuresis associated with vasopressin action suppression. Increased serum AQP4 levels may be a predictive marker for ODS.

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 4; Astrocytes; Behavior, Animal; Benzazepines; Biomarkers; Brain; Chemokines; Cytokines; Cytoprotection; Deamino Arginine Vasopressin; Demyelinating Diseases; Disease Models, Animal; Diuresis; Hyponatremia; Intracranial Hemorrhages; Male; Matrix Metalloproteinases; Minocycline; Neuroprotective Agents; Osmosis; Rats, Sprague-Dawley; Saline Solution, Hypertonic; Sodium; Therapeutics; Time Factors; Tolvaptan; Water-Electrolyte Balance

2014
Minocycline reduces remyelination by suppressing ciliary neurotrophic factor expression after cuprizone-induced demyelination.
    Journal of neurochemistry, 2013, Volume: 127, Issue:2

    Remyelination is disrupted in demyelinating diseases such as multiple sclerosis, but the underlying pathogenetic mechanisms are unclear. In this study, we employed the murine cuprizone model of demyelination, in which remyelination occurs after removal of the toxin from the diet, to examine the cellular and molecular changes during demyelination and remyelination. Microglia accumulated in the corpus callosum during weeks 2-4 of the cuprizone diet, and these cells remained activated 2 weeks after the change to the normal diet. To examine the role of microglia in remyelination, mice were treated with minocycline to inactivate these cells after cuprizone-induced demyelination. Minocycline treatment reduced the number of CC1-positive oligodendrocytes, as well as levels of myelin basic protein (MBP) and CNPase in the remyelination phase. The expression of CNTF mRNA in the corpus callosum increased after 4 weeks on the cuprizone diet and remained high 2 weeks after the change to the normal diet. Minocycline suppressed CNTF expression during the remyelination phase on the normal diet. Primary culture experiments showed that CNTF was produced by microglia in addition to astrocytes. In vitro, CNTF directly affected the differentiation of oligodendrocytic cells. These findings suggest that minocycline reduces remyelination by suppressing CNTF expression by microglia after cuprizone-induced demyelination.

    Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cells, Cultured; Ciliary Neurotrophic Factor; Corpus Callosum; Cuprizone; Demyelinating Diseases; Female; Immunohistochemistry; Mice; Mice, Inbred C57BL; Microglia; Minocycline; Monoamine Oxidase Inhibitors; Myelin Basic Protein; Myelin Sheath; Oligodendroglia; Real-Time Polymerase Chain Reaction

2013
Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-γ plus lipopolysaccharide-induced demyelination.
    Neuroscience, 2011, Jul-28, Volume: 187

    Minocycline has been shown to inhibit microglia reactivity, and to decrease the severity and progression of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. It remained to be examined whether minocycline was also able to promote remyelination. In the present study, myelinating aggregating brain cell cultures were used as a model to study the effects of minocycline on microglial reactivity, demyelination, and remyelination. Cultures were treated simultaneously with two inflammatory agents, interferon-γ (IFN-γ) and lipopolysaccharide (LPS), which caused an inflammatory response accompanied by demyelination. The inflammatory response was characterized by microglial reactivity, upregulation of inflammatory cytokines and iNOS, and increased phophorylation of P38 and P44/42 mitogen activated protein (MAP) kinases. Minocycline inhibited microglial reactivity, and attenuated the increased phophorylation of P38 and P44/42 MAP kinases. Demyelination, determined by a decrease in myelin basic protein (MBP) content and immunoreactivity 48 h after the treatment with the inflammatory agents, was not prevented by minocycline. However, 1 week after demyelination was assessed, the MBP content was restored in presence of minocycline, indicating that remyelination was promoted. Concomitantly, in cultures treated with minocycline, the markers of oligodendrocyte precursors cells (OPCs) and immature oligodendrocytes NG2 and O4, respectively, were decreased compared to cultures treated with the inflammatory agents only. These results suggest that minocycline attenuates microglial reactivity and favors remyelination by enhancing the differentiation of OPCs and immature oligodendrocytes.

    Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Brain; Cell Differentiation; Cells, Cultured; Demyelinating Diseases; Enzyme Activation; Immunohistochemistry; Interferon-gamma; Lipopolysaccharides; Minocycline; Neurons; Oligodendroglia; Rats; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stem Cells

2011
Beneficial effects of minocycline on cuprizone induced cortical demyelination.
    Neurochemical research, 2010, Volume: 35, Issue:9

    In this study, we investigated the potential of minocycline to influence cuprizone induced demyelination in the grey and white matter. To induce demyelination C57BL/6 mice were fed with cuprizone for up to 6 weeks and were analysed at different timepoints (week 0, 4, 5, 6). Mice treated with minocycline had less demyelination of the cortex and corpus callosum compared with sham treated animals. In the cortex decreased numbers of activated and proliferating microglia were found after 6 weeks of cuprizone feeding, while there were no significant effects for microglial infiltration of the corpus callosum. In addition to the beneficial effects on demyelination, minocycline prevented from motor coordination disturbance as shown in the beam walking test. For astrogliosis and the numbers of OPC and oligodendrocytes no treatment effects were found. In summary, minocycline treatment diminished the course of demyelination in the grey and white matter and prevented disturbances in motor coordination.

    Topics: Animals; Anti-Bacterial Agents; Behavior, Animal; Cerebral Cortex; Chelating Agents; Corpus Callosum; Cuprizone; Demyelinating Diseases; Male; Mice; Mice, Inbred C57BL; Minocycline; Motor Activity; Nerve Fibers, Myelinated; Oligodendroglia

2010
Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia.
    Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:12

    Rapid correction of chronic hyponatremia can lead to osmotic demyelination syndrome (ODS), a severe demyelination disease. The microglia that accumulate in the demyelinative lesions may play a detrimental role in the pathogenesis of ODS by producing proinflammatory cytokines, suggesting that they may be a target for therapeutic intervention. Here, we investigated whether minocycline, a selective and potent inhibitor of microglial activation, could protect against ODS in rats. We induced hyponatremia by liquid diet feeding and dDAVP infusion. Rapid correction of the hyponatremia 7 days later resulted in neurologic impairment with severe demyelinative lesions. Activated microglia accumulated at the site of demyelination. Treatment with minocycline within 24 hours of rapid correction, however, was protective: rats exhibited minimal neurologic impairment, and survival improved. Histologic analysis showed that minocycline inhibited demyelination and suppressed the accumulation of microglia at the site of demyelination. Real-time RT-PCR and immunohistochemical analyses showed that minocycline inhibited the activity of microglia and the expression of inflammatory cytokines (e.g. IL-1β, inducible nitric-oxide synthase, and TNF-α), monocyte chemoattractant protein-1, and matrix metalloproteinase-12 in microglia. These results demonstrate that minocycline can protect against ODS by inhibiting the activation and accumulation of microglia at the site of demyelinative lesions, suggesting its possible use in clinical practice.

    Topics: Analysis of Variance; Animals; Cells, Cultured; Cytokines; Demyelinating Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Hyponatremia; Immunohistochemistry; Male; Matrix Metalloproteinases; Microglia; Minocycline; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2010
Minocycline protects against neurologic complications of rapid correction of hyponatremia.
    Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:12

    Osmotic demyelination syndrome is a devastating neurologic condition that occurs after rapid correction of serum sodium in patients with hyponatremia. Pathologic features of this injury include a well-demarcated region of myelin loss, a breakdown of the blood-brain barrier, and infiltration of microglia. The semisynthetic tetracycline minocycline is protective in some animal models of central nervous system injury, including demyelination, suggesting that it may also protect against demyelination resulting from rapid correction of chronic hyponatremia. Using a rat model of osmotic demyelination syndrome, we found that treatment with minocycline significantly decreases brain demyelination, alleviates neurologic manifestations, and reduces mortality associated with rapid correction of hyponatremia. Mechanistically, minocycline decreased the permeability of the blood-brain barrier, inhibited microglial activation, decreased both the expression of IL1α and protein nitrosylation, and reduced the loss of GFAP immunoreactivity. In conclusion, minocycline modifies the course of osmotic demyelination in rats, suggesting its possible therapeutic use in the setting of inadvertent rapid correction of chronic hyponatremia in humans.

    Topics: Analysis of Variance; Animals; Blood-Brain Barrier; Demyelinating Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorescent Antibody Technique; Hyponatremia; Immunohistochemistry; Male; Minocycline; Osmosis; Random Allocation; Rats; Statistics, Nonparametric; Survival Rate

2010
Managing overly rapid correction of chronic hyponatremia: an ounce of prevention or a pound of cure?
    Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:12

    Topics: Animals; Chronic Disease; Demyelinating Diseases; Disease Models, Animal; Humans; Hyponatremia; Minocycline; Osmotic Pressure; Rats; Sodium; Time Factors

2010
The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia.
    Neurochemical research, 2007, Volume: 32, Issue:2

    In order to further characterize the still unknown mechanism of cuprizone-induced demyelination, we investigated its effect on rat primary oligodendroglial cell cultures. Cell viability was not significantly affected by this treatment. However, when concentrations of IFNgamma and/or TNFalpha having no deleterious effects per se on cell viability were added together with cuprizone, cell viability decreased significantly. In mitochondria isolated from cuprizone-treated glial cells, we observed a marked decrease in the activities of the various complexes of the respiratory chain, indicating a disruption of mitochondrial function. An enhancement in oxidant production was also observed in cuprizone and/or TNFalpha-treated oligodendroglial cells. In in vivo experiments, inhibition of microglial activation with minocycline prevented cuprizone-induced demyelination. Based on the above-mentioned results we suggest that these microglial cells appear to have a very active role in cuprizone-induced oligodendroglial cell death and demyelination, through the production and secretion of pro-inflammatory cytokines.

    Topics: Animals; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Cuprizone; Demyelinating Diseases; Immunohistochemistry; Interferon-gamma; Male; Mice; Microglia; Minocycline; Oligodendroglia; Rats; Tumor Necrosis Factor-alpha

2007
Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination.
    Journal of neuroimmunology, 2005, Volume: 158, Issue:1-2

    Minocycline, a tetracycline derivative, disrupts inflammatory processes within the CNS and reduces demyelination in experimental autoimmune encephalomyelitis. Several recent studies indicate that components of the inflammatory response to demyelination may be beneficial for the regenerative process of remyelination. In this study we examined the effects of minocycline on remyelination independent of its effects in limiting immune-mediated white matter damage using a toxin model of demyelination. Demyelinating lesions were induced by injection of ethidium bromide into caudal cerebellar peduncles of adult rats. Minocycline or PBS was administered by twice daily injections from day 1 prior to lesion-induction to post lesion day 3. Remyelination was assessed, blinded to grouping, using standard morphological criteria. The microglia activation within the lesion was assessed by examining the expression of OX-42 and major histocompatibility class II immunoreactivity. The oligodendrocyte progenitor cell (OPC) response was quantified by in situ hybridization using probes for OPC-expressed mRNAs, platelet-derived growth factor receptor-alpha and Olig-1. Minocycline treatment strongly inhibited microglia/macrophage activation at day 1 and day 3 post-lesion induction, and suppressed the OPC response to demyelination. We also found a significant decrease in the extent of oligodendrocyte but not Schwann cell remyelination in the minocycline-treated animals as compared with controls at 3 weeks post-lesion induction. These results indicate that microglia/macrophage activation is an important process for remyelination and further support the concept that suppression of inflammatory response may impair remyelination.

    Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Bromodeoxyuridine; CD11b Antigen; Cell Count; Cells, Cultured; Cerebellum; Demyelinating Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Ethidium; Female; Fluorescent Antibody Technique; Genes, MHC Class II; In Situ Hybridization; Microglia; Minocycline; Oligodendroglia; Rats; Staining and Labeling; Stem Cells; Time Factors

2005
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.
    Journal of neuroimmunology, 2005, Volume: 158, Issue:1-2

    There have been significant advances in the treatment of multiple sclerosis (MS) in recent years, but further improvement in therapy is required as not all patients have responded optimally. An approach to enhancing MS treatment is to combine drugs that impact on different aspects of the disease process. We have described that the tetracycline derivative, minocycline, attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a model of MS. Here, we have evaluated the combination of minocycline and glatiramer acetate (GA), a current therapy in MS, on the course of EAE in mice. This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination.

    Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Cytokines; Demyelinating Diseases; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Glatiramer Acetate; Immunosuppressive Agents; Inflammation; Lymph Nodes; Mice; Mice, Inbred C57BL; Minocycline; Multiple Sclerosis; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Peptides; Silver Staining; Spleen; Time Factors

2005
Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors.
    Glia, 2003, Jan-15, Volume: 41, Issue:2

    To evaluate the functional consequence of microglial activation in vivo, oligodendroglial progenitors were transplanted into the spinal cord of Long Evans shaker, a myelin mutant rat in which myelin defects are associated with progressive microglial activation. Cells grafted into neonatal rats at the initiation of gliosis successfully myelinated axons. However, cells transplanted during peak microglial activation did not lead to myelination due to death of the grafted cells within 3 days after transplantation. Pretreatment of these animals with minocycline, a tetracycline derivative, resulted in cell survival and myelination by the grafted cells. In culture, minocycline did not affect the survival, proliferation, or differentiation of oligodendroglial progenitors. Hence, minocycline likely modulates the function of reactive glia in vivo to promote the survival and myelination of transplanted oligodendroglial progenitors.

    Topics: Animals; Animals, Newborn; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Demyelinating Diseases; Disease Models, Animal; Gliosis; Graft Survival; Immunohistochemistry; Microglia; Microscopy, Electron; Minocycline; Neurodegenerative Diseases; Oligodendroglia; Rats; Rats, Long-Evans; Rats, Mutant Strains; Recovery of Function; Stem Cells

2003